Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction

被引:9
|
作者
Chiorescu, Roxana Mihaela [1 ,2 ]
Lazar, Roxana-Daiana [3 ]
Buksa, Sandor-Botond [2 ]
Mocan, Mihaela [1 ,2 ]
Blendea, Dan [1 ,3 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med, Cluj Napoca, Romania
[2] Emergency Clin Cty Hosp, Dept Internal Med, Cluj Napoca, Romania
[3] Nicolae Stancioiu Heart Inst, Cluj Napoca, Romania
来源
关键词
heart failure; volume overload; physiopathology; edema; biomarkers; FAMILY-MEMBER ST2; ALDOSTERONE; INHIBITION; COPEPTIN; APELIN; ACE2; SACUBITRIL/VALSARTAN; ADRENOMEDULLIN; ASSOCIATION; MECHANISMS;
D O I
10.3389/fcvm.2022.910100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
From a pathogenetic point of view, heart failure (HF) is characterized by the activation of several neurohumoral pathways with a role in maintaining the cardiac output and the adequate perfusion pressure in target organs and tissues. Decreased cardiac output in HF with reduced ejection fraction causes activation of the sympathetic nervous system, the renin angiotensin aldosterone system, arginine-vasopressin system, natriuretic peptides, and endothelin, all of which cause water and salt retention in the body. As a result, patients will present clinically as the main symptoms: dyspnea and peripheral edema caused by fluid redistribution to the lungs and/or by fluid overload. By studying these pathophysiological mechanisms, biomarkers with a prognostic and therapeutic role in the management of edema were identified in patients with HF with low ejection fraction. This review aims to summarize the current data from the specialty literature of such biomarkers with a role in the pathogenesis of edema in HF with low ejection fraction. These biomarkers may be the basis for risk stratification and the development of new therapeutic means in the treatment of edema in these patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Pressure overload is associated with right ventricular dyssynchrony in heart failure with reduced ejection fraction
    Monzo, Luca
    Tupy, Marek
    Borlaug, Barry A.
    Reichenbach, Adrian
    Jurcova, Ivana
    Benes, Jan
    Mlateckova, Lenka
    Ters, Jiri
    Kautzner, Josef
    Melenovsky, Vojtech
    ESC HEART FAILURE, 2024, 11 (02): : 1097 - 1109
  • [22] Biomarkers in heart failure with preserved versus reduced left ventricular ejection fraction
    Van Wijk, S.
    Van Empel, V.
    Maeder, M. T.
    Muzzarelli, S.
    Jeker, U.
    Dieterle, T.
    Handschin, R.
    Kiencke, S.
    Pfisterer, M. E.
    Brunner-La Rocca, H. P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 92 - 92
  • [23] Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?
    Squire, Iain B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (12) : 1648 - 1650
  • [24] The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
    Takvorian, Katherine S. S.
    Wang, Dongyu
    Courchesne, Paul
    Vasan, Ramachandran S. S.
    Benjamin, Emelia J. J.
    Cheng, Susan
    Larson, Martin G. G.
    Levy, Daniel
    Ho, Jennifer E. E.
    CIRCULATION-HEART FAILURE, 2023, 16 (01) : E009446
  • [25] Novel biomarkers in heart failure with reduced and preserved ejection fraction in the general population
    Sinning, C.
    Kempf, T.
    Schnabel, R.
    Zengin, E.
    Ojeda, F.
    Wild, P.
    Lackner, K.
    Munzel, T.
    Blankenberg, S.
    Wollert, K. C.
    Zeller, T.
    Westermann, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 220 - 221
  • [26] Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
    de Boer, Rudolf A.
    Nayor, Matthew
    deFilippi, Christopher R.
    Enserro, Danielle
    Bhambhani, Vijeta
    Kizer, Jorge R.
    Blaha, Michael J.
    Brouwers, Frank P.
    Cushman, Mary
    Lima, Joao A. C.
    Bahrami, Hossein
    van der Harst, Pim
    Wang, Thomas J.
    Gansevoort, Ron T.
    Fox, Caroline S.
    Gaggin, Hanna K.
    Kop, Willem J.
    Liu, Kiang
    Vasan, Ramachandran S.
    Psaty, Bruce M.
    Lee, Douglas S.
    Hillege, Hans L.
    Bartz, Traci M.
    Benjamin, Emelia J.
    Chan, Cheeling
    Allison, Matthew
    Gardin, Julius M.
    Januzzi, James L., Jr.
    Shah, Sanjiv J.
    Levy, Daniel
    Herrington, David M.
    Larson, Martin G.
    van Gilst, Wiek H.
    Gottdiener, John S.
    Bertoni, Alain G.
    Ho, Jennifer E.
    JAMA CARDIOLOGY, 2018, 3 (03) : 215 - 224
  • [27] Biomarkers in heart failure with preserved ejection fraction
    W. C. Meijers
    A. R. van der Velde
    R. A. de Boer
    Netherlands Heart Journal, 2016, 24 : 252 - 258
  • [28] Biomarkers in heart failure with preserved ejection fraction
    Meijers, W. C.
    van der Velde, A. R.
    de Boer, R. A.
    NETHERLANDS HEART JOURNAL, 2016, 24 (04) : 252 - 258
  • [29] Biomarkers in Heart Failure with Preserved Ejection Fraction
    Bayes-Genis, Antoni
    Cediel, German
    Domingo, Mar
    Codina, Pau
    Santiago, Evelyn
    Lupon, Josep
    CARDIAC FAILURE REVIEW, 2022, 8
  • [30] CONTRIBUTIONS OF CARDIAC DYSFUNCTION AND VOLUME STATUS IN HEART FAILURE WITH REDUCED EJECTION FRACTION
    Skidan, Viktoriia I.
    Goda, Ahmed
    Nkomo, Vuyisile Tlhopane
    Pislaru, Cristina
    Pislaru, Sorin
    Miller, Wayne L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 739 - 739